Introduction {#jbm410024-sec-0002}
============

There is currently a crisis in the treatment of osteoporosis, with a call to action by multiple international professional societies to aggressively reduce fracture risk in our aging population.[1](#jbm410024-bib-0001){ref-type="ref"} Despite the availability of effective antiresorptive osteoporosis drugs, namely bisphosphonates and denosumab, treatment rates after hip fracture---in patients at the highest risk for subsequent fractures---have halved from 40% in 2002 to 21% in 2011.[1](#jbm410024-bib-0001){ref-type="ref"} This crisis is driven by in large part by fear of rare complications of antiresorptive drugs, such as atypical femoral fractures (AFFs) (Fig. [1](#jbm410024-fig-0001){ref-type="fig"}).[2](#jbm410024-bib-0002){ref-type="ref"}, [3](#jbm410024-bib-0003){ref-type="ref"} Despite the significant burden of osteoporosis and fractures globally, since the first clinical reports of bisphosphonate‐associated AFFs in 2005[4](#jbm410024-bib-0004){ref-type="ref"} and the subsequent FDA safety report in 2010,[5](#jbm410024-bib-0005){ref-type="ref"} there has been a 50% decline in the use of these effective osteoporosis therapies.[6](#jbm410024-bib-0006){ref-type="ref"}

![X‐ray series of a 61‐year‐old woman with postmenopausal osteoporosis presenting with prodromal left thigh pain in the setting of 11 years of alendronate therapy. An initial radiograph of the left femur demonstrated a transverse midshaft lateral stress fracture consistent with an incomplete atypical femoral fracture (*A*). After a minimal trauma fall, the fracture progressed to a complete fracture (*B*), and this required surgical fixation with an intramedullary nail (*C*). Reproduced from Nguyen et al. Bone Rep. 2017;6:34--7.](JBM4-2-1-g001){#jbm410024-fig-0001}

Currently, the pathogenesis of AFFs is not known, but AFFs have also been described in individuals with monogenetic bone disorders and can occur in bisphosphonate‐naïve individuals, who comprise about 7% of cases.[2](#jbm410024-bib-0002){ref-type="ref"}, [3](#jbm410024-bib-0003){ref-type="ref"} As such, it is likely that genetic variants exist that predispose to AFFs. This article reviews and summarizes the evidence for genetic factors in individuals with AFFs after first discussing the epidemiology and clinical problem of this condition.

Osteoporosis and anti‐osteoporosis drugs {#jbm410024-sec-0003}
----------------------------------------

Osteoporosis is a condition with reduced bone strength due to abnormalities in the material composition and microstructure of bone predisposing to fractures. Hip fractures are catastrophic events resulting in chronic pain, disability, and increased mortality up to 35% within 12 months.[7](#jbm410024-bib-0007){ref-type="ref"} Bisphosphonates are well‐established drugs for the management of osteoporosis. They are effective at reducing the risk of vertebral fractures by up to 70%[8](#jbm410024-bib-0008){ref-type="ref"} and also reduce nonvertebral and hip fractures.[9](#jbm410024-bib-0009){ref-type="ref"} They have been approved treatments for osteoporosis for more than 2 decades.

Bisphosphonates are structural analogs of inorganic pyrophosphate and inhibit bone resorption by binding avidly to bone mineral surfaces, are subsequently internalized by bone‐resorbing osteoclasts, whereby they disrupt various biochemical processes.[10](#jbm410024-bib-0010){ref-type="ref"} In particular, nitrogen‐containing bisphosphonates inhibit farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway. This pathway is important for the biosynthesis of isoprenoids, molecules essential for multiple cellular processes. Disruption of this pathway affects osteoclast function and viability, ultimately resulting in reduced bone resorption.

The problem of atypical femoral fractures {#jbm410024-sec-0004}
-----------------------------------------

In 2005, Odvina and colleagues published the first case series of femoral shaft fractures associated with long‐term bisphosphonate use and showed evidence of markedly suppressed bone formation on a bone biopsy.[4](#jbm410024-bib-0004){ref-type="ref"} A subsequent series of femoral fractures from Singapore in 2007[11](#jbm410024-bib-0011){ref-type="ref"} emphasized the unusual location of this fracture in the subtrochanteric region. This region (from just distal to the lesser trochanter to just proximal to the supracondylar flare of the femur) is notably resilient to traumatic injuries.[12](#jbm410024-bib-0012){ref-type="ref"} In 2010, the ASBMR convened an international Task Force to commission a report on and to create a case definition of AFF.[2](#jbm410024-bib-0002){ref-type="ref"} This case definition was subsequently revised in 2013 (Table [1](#jbm410024-tbl-0001){ref-type="table"}).[3](#jbm410024-bib-0003){ref-type="ref"}

###### 

ASBMR TASK Force Revised Case Definition of AFFs

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AFF must be located along the femoral diaphysis from just distal to the lesser trochanter to just proximal to the supracondylar flare.
  At least four of five Major Features must be present. No Minor Features are required.
  Major features Minimal or no trauma as in a fall from a standing height or lessThe fracture line originates at the lateral cortex and is transverse, although it may become oblique as it progresses mediallyComplete fractures extend through both cortices and may be associated with a medial spike; incomplete fractures involve only the lateral cortexThe fracture is non‐ or minimally comminutedLocalized periosteal or endosteal thickening of the lateral cortex is present at the fracture site ("beaking" or "flaring")
  Minor features Generalized increase in cortical thickness of the femoral diaphysesUnilateral or bilateral prodromal symptoms such as dull or aching pain in the groin or thighBilateral incomplete or complete femoral diaphysis fracturesDelayed fracture healing
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Epidemiology and consequences of AFFs {#jbm410024-sec-0005}
-------------------------------------

In a population‐based Swedish study including 12,777 women aged ≥55 years with femoral fractures, 59 AFFs were identified, of which 46 occurred in bisphosphonate users.[13](#jbm410024-bib-0013){ref-type="ref"} Linkage to the Swedish Prescribed Drug Register identified that 46 AFFs occurred in 83,311 women ever prescribed bisphosphonates in the preceding 3 years, whereas only 13 cases of bisphosphonate‐naïve AFFs occurred out of 1,437,820 Swedish women aged ≥55 years who were not prescribed bisphosphonates. The age‐adjusted relative risk of AFF with any use of bisphosphonates was 47.3.

Meier and colleagues found that the proportion of patients exposed to bisphosphonates was higher in patients with AFFs than in those with non‐atypical fractures (82.1% versus 6.4%).[14](#jbm410024-bib-0014){ref-type="ref"} The risk of AFF increases with longer duration of bisphosphonate exposure (1.8 per 100,000 cases per year after 0.1 to 1.9 years, rising to 113.1 per 100,000 cases per year for 8.0 to 9.0 years of use).[15](#jbm410024-bib-0015){ref-type="ref"} AFFs are also associated with a younger cohort,[16](#jbm410024-bib-0016){ref-type="ref"} Asian ethnicity,[17](#jbm410024-bib-0017){ref-type="ref"} a previous stress fracture of the contralateral femur,[14](#jbm410024-bib-0014){ref-type="ref"} and glucocorticoid use.[2](#jbm410024-bib-0002){ref-type="ref"}

Although the incidence of AFF is relatively low, the effect of a painful, spontaneous femoral fracture is devastating to the individual. In addition, up to 40% of AFFs occur in bilateral femora and delayed healing is common, resulting in prolonged immobilization. Prodromal pain occurs in more than 70%.[2](#jbm410024-bib-0002){ref-type="ref"}

Pathophysiology: proposed mechanisms {#jbm410024-sec-0006}
------------------------------------

Although the pathogenesis of AFFs remains largely unknown, its epidemiological association with bisphosphonate therapy led to several proposed mechanisms. Bisphosphonates alter collagen maturity and cross‐linking, as indicated by the increase in pyridinoline (PYD)/deoxypyridinoline (DPD) ratio, increasing the strength but also stiffness of bone.[18](#jbm410024-bib-0018){ref-type="ref"}, [19](#jbm410024-bib-0019){ref-type="ref"} Moreover, reducing bone remodeling also increases pentosidine, which interacts with collagen through oxidative nonenzymatic cross‐linkage, leading to advanced glycation end product accumulation, which results in reduced toughness. Both effects increase matrix stiffness and consequently reduce the peak‐tolerated strain. The stiffening by increased matrix mineralization and pentosidine cross‐linking reduces ductility; the structure becomes more brittle.[20](#jbm410024-bib-0020){ref-type="ref"}, [21](#jbm410024-bib-0021){ref-type="ref"}

Also, more homogeneously mineralized bone tissue facilitates fracture crack initiation and propagation.[22](#jbm410024-bib-0022){ref-type="ref"}, [23](#jbm410024-bib-0023){ref-type="ref"} Thus, remodeling suppression increases microfracture burden, allowing cracks to lengthen and reducing crack removal.[24](#jbm410024-bib-0024){ref-type="ref"}, [25](#jbm410024-bib-0025){ref-type="ref"} Microdamage accumulation may be further compounded by the preferential uptake of bisphosphonates at sites of high bone remodeling, including sites of stress fractures. Therefore, by suppressing remodeling at these local sites, bisphosphonates could potentially affect the intracortical repair of a developing stress fracture such as an AFF, allowing crack progression to a complete fracture.

Iliac crest bone biopsies from AFF cases showed reduced bone turnover in most cases, as would be expected with bisphosphonate treatment, but this has not been a universal finding.[2](#jbm410024-bib-0002){ref-type="ref"} In bone biopsies obtained close to the fracture site in AFF cases, both decreased and increased bone remodeling have been described, although the latter may be influenced by the recent fracture and may not be indicative of the underlying pathogenic mechanism of AFFs.

Hypotheses and aims {#jbm410024-sec-0007}
-------------------

The rarity of AFFs amongst the millions of bisphosphonate users worldwide is suggestive of an individual susceptibility, which could be an underlying genetic predisposition.

The potential importance of genetic factors is supported by the occurrence of AFFs in bisphosphonate‐naïve individuals.[13](#jbm410024-bib-0013){ref-type="ref"}, [26](#jbm410024-bib-0026){ref-type="ref"}, [27](#jbm410024-bib-0027){ref-type="ref"} Some of these bisphosphonate‐naïve individuals were found to have an underlying monogenetic bone disease, such as hypophosphatasia, pycnodysostosis, osteopetrosis, X‐linked hypophosphatemia (XLH), and osteoporosis pseudoglioma syndrome (OPPG), leading to the hypothesis that carriers of pathogenic mutations (very rare variants) or polymorphisms (common variants) in genes related to these monogenetic bone diseases may predispose to AFFs. Mild unrecognized forms of such heritable bone diseases may underlie the etiology of AFFs in some patients. Additionally, AFFs have been reported in patients with osteogenesis imperfecta (OI) and X‐linked osteoporosis based on a *PLS3* mutation. Yet these cases may be related to the coexistent antiresorptive treatment rather than the underlying genetic condition, and no analysis has ever been done to investigate whether AFFs occur more frequently in patients with these genetic bone disorders. Even more suggestive of a genetic background of AFFs is the identification of 2 families with multiple family members with AFF.[28](#jbm410024-bib-0028){ref-type="ref"}, [29](#jbm410024-bib-0029){ref-type="ref"}

Furthermore, racial differences in risk and site of AFFs exist, which may be consistent with a genetic background. The age‐adjusted relative risk for AFFs in Asians is 6.6 compared with white women corrected for current bisphosphonate use and duration of bisphosphonate treatment.[17](#jbm410024-bib-0017){ref-type="ref"} Schilcher and colleagues showed ethnic differences in location of the AFFs, with fractures mainly occurring in the subtrochanteric region in Singapore, compared with diaphyseal in Sweden.[30](#jbm410024-bib-0030){ref-type="ref"} The differences may be related to femoral geometric parameters that are more common in Asian women, such as increased femoral bowing and smaller neck‐shaft angles.[31](#jbm410024-bib-0031){ref-type="ref"}, [32](#jbm410024-bib-0032){ref-type="ref"}, [33](#jbm410024-bib-0033){ref-type="ref"}, [34](#jbm410024-bib-0034){ref-type="ref"} Increased femoral curvature may lead to an altered distribution of loading with more tensile strain on the lateral side and more compression on the medial side of the femur. This imbalance of biomechanical stresses with increased femoral bowing might contribute to spontaneous, transverse femoral fractures such as AFFs.[35](#jbm410024-bib-0035){ref-type="ref"}

We speculate that genetic factors may also interact with clinical risk factors for AFFs, including a high number of comorbid conditions, and concomitant medications, like glucocorticoids.[2](#jbm410024-bib-0002){ref-type="ref"}

The aim of this systematic review is to gather the data of AFF in relation to genetics and scrutinize the available evidence of genetic risk factors underlying the susceptibility for AFFs and to inform future directions for further research.

Methods {#jbm410024-sec-0008}
=======

We conducted a structured literature search of electronic databases, including Embase, Medline, Web of Science, Cochrane Central, and Google Scholar, and hand‐searching of conference abstracts/reference lists using the following key words: femur/femoral fracture or subtrochanteric fracture, atypical and drug‐induced disease, bisphosphonates, antiresorptives, and denosumab.

We identified 2566 citations, and authors HHN and DMvdL independently reviewed citations with the following inclusion criteria: (i) cases of AFFs in monogenetic bone diseases, and (ii) genetic studies in individuals with an AFF. Articles were only included if images of the femoral fracture were published and fulfilled the ASBMR case definition (Table [1](#jbm410024-tbl-0001){ref-type="table"}) or if the authors used the recent ASBMR case definition to define the presence of AFFs. Twenty‐six citations fulfilled the inclusion criteria and are described below. During preparation of this manuscript, two additional published articles and a conference abstract relevant to this topic were identified and also included in this review, making a total of 29 included studies.

Results and Discussion {#jbm410024-sec-0009}
======================

Reports of AFFs occurring in monogenetic bone disorders {#jbm410024-sec-0010}
-------------------------------------------------------

Subtrochanteric femoral fractures fulfilling the ASBMR case definition of AFF were identified in 7 monogenetic bone disorders. These findings are summarized in Table [2](#jbm410024-tbl-0002){ref-type="table"} and explored further below.

###### 

List of Monogenetic Bone Disorders Associated With Atypical Femoral Fractures (AFFs)

  Monogenetic bone disorder                                                                                                                                                                                                                                                            Genes associated with disorder                                  Sex       Age (yrs)   Bilateral AFF *n*   BP exposure *n*   Disorder diagnosed following AFF *n*
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------- --------- ----------- ------------------- ----------------- --------------------------------------
  *Hypophosphatasia* [36](#jbm410024-bib-0036){ref-type="ref"}, [37](#jbm410024-bib-0037){ref-type="ref"}, [38](#jbm410024-bib-0038){ref-type="ref"}, [39](#jbm410024-bib-0039){ref-type="ref"}                                                                                        ALPL                                                            4 F       50--55      4                   1                 4
  *XLH* [41](#jbm410024-bib-0041){ref-type="ref"}                                                                                                                                                                                                                                      PHEX                                                            1 M       27          0                   0                 0
  *Pycnodysostosis* [44](#jbm410024-bib-0044){ref-type="ref"}, [45](#jbm410024-bib-0045){ref-type="ref"}, [46](#jbm410024-bib-0046){ref-type="ref"}, [47](#jbm410024-bib-0047){ref-type="ref"}, [48](#jbm410024-bib-0048){ref-type="ref"}, [49](#jbm410024-bib-0049){ref-type="ref"}   CTSK                                                            3 M 4 F   23--55      3                   0                 2
  *Osteopetrosis* [51](#jbm410024-bib-0051){ref-type="ref"}, [52](#jbm410024-bib-0052){ref-type="ref"}, [53](#jbm410024-bib-0053){ref-type="ref"}                                                                                                                                      TCIRG1, CLCN7, OSTM1, PLEKHM1, SNZ10, TNFS11, TNFRSF11A, CA11   4 F       21--56      2                   0                 1
  *OPPG* [57](#jbm410024-bib-0057){ref-type="ref"}                                                                                                                                                                                                                                     LRP5                                                            1 M       38          0                   0                 1
  *OI* [61](#jbm410024-bib-0061){ref-type="ref"}, [62](#jbm410024-bib-0062){ref-type="ref"}, [63](#jbm410024-bib-0063){ref-type="ref"}, [64](#jbm410024-bib-0064){ref-type="ref"}, [65](#jbm410024-bib-0065){ref-type="ref"}                                                           COL1A1/1A2, CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, PLOD2, SP7   4 F 1 M   11--75      2                   5                 0
  *X‐linked osteoporosis* [70](#jbm410024-bib-0070){ref-type="ref"}                                                                                                                                                                                                                    PLS3                                                            1 M       18          0                   1                 0

AFF = atypical femoral fracture, F = female, M = male, BP = bisphosphonate, XLH = X‐linked hypophosphataemia, OPPG = osteoporosis pseudoglioma syndrome, OI = osteogenesis imperfect.
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The 7 bone disorders included primary defects in bone mineralization, bone remodeling, collagen synthesis and structure, and osteocyte function (Fig. [2](#jbm410024-fig-0002){ref-type="fig"}). AFFs were also reported in juvenile forms of osteoporosis linked with long‐term bisphosphonate use and may reflect a pediatric variant of bisphosphonate‐associated AFF. These cases provide insight into the possible pathogenesis of AFFs and indicate potential candidate genes that may encode for variants predisposing to AFF. When dealing with bisphosphonate‐naïve patients with AFFs, clinicians may need to carefully consider and exclude these underlying genetic conditions in their diagnostic assessment for secondary causes of skeletal fragility.

![Genes implicated in atypical femoral fractures and their relationship to bone remodeling and bone matrix. HSC = hematopoietic stem cell; MSC = mesenchymal stem cell.](JBM4-2-1-g002){#jbm410024-fig-0002}

### Mineralization defect {#jbm410024-sec-0011}

*Hypophosphatasia*: The literature search identified 4 cases of AFFs occurring in adult hypophosphatasia,[36](#jbm410024-bib-0036){ref-type="ref"}, [37](#jbm410024-bib-0037){ref-type="ref"}, [38](#jbm410024-bib-0038){ref-type="ref"}, [39](#jbm410024-bib-0039){ref-type="ref"} in all of whom the genetic condition was unmasked after the femoral fracture. Three cases were bisphosphonate‐naïve and in 1 case, reported by Sutton and colleagues, of bilateral atraumatic AFFs occurred simultaneously in a postmenopausal woman after 4 years of bisphosphonate therapy for osteoporosis.[38](#jbm410024-bib-0038){ref-type="ref"}

Hypophosphatasia is an inborn error of metabolism characterized by low alkaline phosphatase (ALP) levels, due to a loss‐of‐function mutation in the *ALPL* gene (also known as *TNSALP* gene) that encodes the tissue nonspecific ALP.[40](#jbm410024-bib-0040){ref-type="ref"} This defect in enzyme function leads to accumulation of substrates, such as inorganic pyrophosphate, pyridoxal 5\' phosphate (active form of vitamin B6), and phosphoethanolamine. Inorganic pyrophosphate is an inhibitor of mineralization, and its accumulation in hypophosphatasia results in skeletal and dental manifestations.

The clinical spectrum of hypophosphatasia is broad and can range from severe lethal forms in infancy to mild forms in adulthood or with only dental complications (odontohypophosphatasia).[40](#jbm410024-bib-0040){ref-type="ref"} Skeletal manifestations in adulthood may include osteopenia, poorly healing stress fractures of the metatarsal bones, and pseudo‐fractures. The pseudo‐fractures commonly occur on the lateral side of the femoral shaft and can resemble bisphosphonate‐associated AFFs.[41](#jbm410024-bib-0041){ref-type="ref"}

The similarity in the pseudo‐fractures found in hypophosphatasia and the AFFs that occur in patients with osteoporosis treated with bisphosphonates may be explained by the fact that bisphosphonates are synthetic analogs of inorganic pyrophosphate resistant to ALP activity. There has been one case report of pyrophosphate accumulation at a site of a bisphosphonate‐associated AFF.[42](#jbm410024-bib-0042){ref-type="ref"} Alternatively, the presence of AFFs found in bisphosphonate‐naïve patients with hypoposphatasia may suggest that variants in the *ALPL* gene may be implicated in the pathogenesis of AFFs, independent of bisphosphonate exposure. Speculation also exists as to whether bisphosphonate therapy in individuals with mild forms of hypophosphatasia may precipitate AFFs. Targeted genetic testing of the *ALPL* gene in small cohorts of individuals with AFF have been conducted, and results will be described further below.

*X‐linked hypophosphatemia (XLH)*: Whyte and colleagues reported that pseudo‐fractures in the lateral cortex of the femoral shaft can occur in XLH similar to AFFs.[41](#jbm410024-bib-0041){ref-type="ref"} In this report, a 27‐year‐old bisphosphonate‐naïve male with XLH had radiological features of an incomplete AFF.

XLH is the most common form of hereditary rickets and is caused by loss‐of‐function mutations of the *PHEX* gene.[43](#jbm410024-bib-0043){ref-type="ref"} Biochemical findings in this condition are hypophosphatemia with renal phosphate wasting and associated inappropriately low 1,25‐hydroxyvitamin D levels and high FGF‐23 levels. Low bone mineral density, rickets, and/or osteomalacia with shortening and deformities of the lower limbs are common features of this condition.

### Defect in bone remodeling {#jbm410024-sec-0012}

*Pycnodysostosis*: Subtrochanteric femoral fractures fulfilling criteria for AFFs have been described in 7 adult cases of pycnodysostosis. In 3 of these cases, pycnodysostosis was unmasked after the femoral fracture.[44](#jbm410024-bib-0044){ref-type="ref"}, [45](#jbm410024-bib-0045){ref-type="ref"}, [46](#jbm410024-bib-0046){ref-type="ref"}, [47](#jbm410024-bib-0047){ref-type="ref"}, [48](#jbm410024-bib-0048){ref-type="ref"}, [49](#jbm410024-bib-0049){ref-type="ref"} Five cases were bisphosphonate‐naïve, whereas prior bisphosphonate use was unknown in the remaining 2 cases. Bilateral AFFs occurred in 4 cases of pycnodysostosis. Nakase and colleagues[45](#jbm410024-bib-0045){ref-type="ref"} reported delayed healing of the femoral shaft fracture of up to 3 years in 2 patients with pycnodysostosis.

Pycnodysostosis is a rare, autosomal recessive disorder of osteoclast function, characterized by short stature, osteosclerosis, pathological fractures with poor healing, acro‐osteolysis of the terminal phalanges, and craniofacial dysmorphisms.[50](#jbm410024-bib-0050){ref-type="ref"} It is caused by mutations in the *CTSK* gene resulting in deficiency of cathepsin K activity. Cathepsin K is an enzyme that is highly expressed in osteoclasts and is responsible for degradation of bone matrix proteins during osteoclast‐mediated bone resorption. The defect in osteoclast activity leads to osteosclerosis, increased bone density, abnormal bone matrix, and brittle bones, predisposing to pathological fractures of the long bones. Pycnodysostosis is managed symptomatically, and antiresorptive therapy has no place/is not indicated in this condition. The occurrence of AFFs in the absence of bisphosphonate use in pycnodysostosis, as described in these case reports, raises the possibility that genetic variants of the *CTSK* gene may predispose individuals to AFF.

*Osteopetrosis*: Our literature search identified 4 cases of AFFs occurring in bisphosphonate‐naïve individuals with osteopetrosis, although the underlying mutated gene was not reported in these articles.[51](#jbm410024-bib-0051){ref-type="ref"}, [52](#jbm410024-bib-0052){ref-type="ref"}, [53](#jbm410024-bib-0053){ref-type="ref"} All authors described the surgical difficulties in the repair of the subtrochanteric femoral fractures in sclerotic bone.

Osteopetrosis is a class of rare heterogeneous genetic disorders characterized by high bone mass due to a failure of osteoclast‐mediated bone resorption.[54](#jbm410024-bib-0054){ref-type="ref"} Mutations in 8 genes have been described, including *TCIRG1, OSTM1, PLEKHM1, SNZ10, TNFSF11, TNFRSF11A, CAII*, and *CLCN7*. Despite increased bone density, the sclerotic bone is brittle and fragility fractures occur,[55](#jbm410024-bib-0055){ref-type="ref"} and antiresorptive therapies are avoided in this condition. Other clinical features include craniofacial deformities, neurological compression from sclerotic bone, bone marrow failure due to reduction of bone marrow space, complications from extramedullary hematopoiesis, osteoarthritis, and dental complications.

*Osteoporosis pseudoglioma syndrome (OPPG)*: OPPG is a rare, autosomal recessive form of juvenile osteoporosis caused by a loss‐of‐function mutation in the *LRP5* gene.[56](#jbm410024-bib-0056){ref-type="ref"} We identified a single case report of an AFF occurring in a 40‐year‐old bisphosphonate‐naïve male with OPPG, who had multiple fragility fractures since childhood and evidence of low bone turnover on bone biopsy.[57](#jbm410024-bib-0057){ref-type="ref"} This is the only report of an AFF occurring in a genetic condition with primary osteoblast dysfunction. LRP5 acts through the osteoblastic Wnt/β‐catenin canonical signaling pathway to regulate bone formation.[56](#jbm410024-bib-0056){ref-type="ref"} Homozygous and compound heterozygous loss‐of‐function mutations in *LRP5* result in OPPG, whereas gain‐of‐function mutations in *LRP5* results in high bone mass. Common polymorphisms of *LRP5* can affect bone density in the general population.[58](#jbm410024-bib-0058){ref-type="ref"}

### Defect in collagen synthesis and structure {#jbm410024-sec-0013}

*Osteogenesis imperfecta (OI)*: OI is a heterogeneous, heritable connective tissue disorder with prominent skeletal features, including low bone mass, hypermineralized bone matrix, multiple fragility fractures, bone deformities, and short stature.[59](#jbm410024-bib-0059){ref-type="ref"} Bisphosphonates are widely used therapies in children and adults with this condition. However, in a recent Cochrane Review of bisphosphonate use in OI, the authors concluded that although bisphosphonates may improve bone mass, the evidence for long‐term fracture reduction is unclear.[60](#jbm410024-bib-0060){ref-type="ref"}

To date, 4 case reports have been published describing classical AFFs in adults with OI.[61](#jbm410024-bib-0061){ref-type="ref"}, [62](#jbm410024-bib-0062){ref-type="ref"}, [63](#jbm410024-bib-0063){ref-type="ref"}, [64](#jbm410024-bib-0064){ref-type="ref"} All cases had prior bisphosphonate exposure. Vasanwala and colleagues reported bilateral AFFs in an 11‐year‐old female with OI after 5 years of pamidronate therapy,[65](#jbm410024-bib-0065){ref-type="ref"} representing the only reported case of classical AFFs occurring in a pediatric patient with OI.

Hegazy and colleagues published a case series of AFF occurring in 6 pediatric OI patients,[66](#jbm410024-bib-0066){ref-type="ref"} who all had prior long‐term bisphosphonate therapy. However, the stress fractures occurred at periprosthetic sites and would technically be excluded from the ASBMR case definition. The occurrence of bisphosphonate‐associated AFF in children raises the question of long‐term safety of these drugs in pediatric populations.

A retrospective study by Nicolaou and colleagues demonstrated that a different pattern of femoral shaft fractures occurred in patients with OI and bisphosphonate use compared with a historical cohort of OI patients without bisphosphonate therapy, with more fractures occurring in the proximal third of the femur in children treated with bisphosphonates, whereas mid‐diaphyseal femoral fractures were more common in a control group without bisphosphonate exposure.[67](#jbm410024-bib-0067){ref-type="ref"}

OI is most often caused by defects in type 1 collagen synthesis (encoded by *COL1A1* and *COL1A2* genes), resulting in aberrant protein posttranslational modification, folding, intracellular transport, and bone matrix incorporation.[68](#jbm410024-bib-0068){ref-type="ref"} This either results in collagen protein deficiency or mutant collagen protein synthesis and leads to abnormal composition and organization of bone matrix, which increases bone stiffness and skeletal fragility.

Mice models suggest that skeletal microdamage levels are increased in OI, resulting in higher bone remodeling activity to target microcrack repair.[69](#jbm410024-bib-0069){ref-type="ref"} As bisphosphonates suppress bone remodeling and may impede microcrack repair, its use in patients with OI may result in even higher levels of microdamage accumulation and compromised bone toughness, predisposing to stress fracture development and AFF.

Although bisphosphonate treatment has been used to improve bone density in OI, they do not reverse the underlying impaired collagen defect. AFFs have been described in adult cases with OI and bisphosphonate exposure, whereas the risk of AFFs and the long‐term safety of bisphosphonate use in pediatric populations remains unclear.

### Defect in osteocyte function {#jbm410024-sec-0014}

*X‐linked osteoporosis*: Our group has published a case report on an AFF occurring in an 18‐year‐old male with X‐linked osteoporosis who had been treated with bisphosphonates for 9 years.[70](#jbm410024-bib-0070){ref-type="ref"} X‐linked osteoporosis is a form of juvenile osteoporosis caused by pathogenic variants in *PLS3*, located on the X chromosome, encoding for the protein plastin 3.[71](#jbm410024-bib-0071){ref-type="ref"} Mutations in this gene have been associated with skeletal fragility in hemizygous males, whereas the clinical phenotype of heterozygous females may vary, ranging from normal bone mineral density and an absence of fractures to early‐onset osteoporosis. Affected individuals can present in childhood with low bone density, vertebral compression fractures, and long bone fractures.[72](#jbm410024-bib-0072){ref-type="ref"} Although the exact mechanism through which PLS3 mutations cause skeletal manifestations is unclear, decreased mechanosensing of osteocytes was proposed.[71](#jbm410024-bib-0071){ref-type="ref"} This is supported by a recent finding of altered osteocyte protein expression in low‐turnover osteoporosis caused by mutations in *WNT1* and *PLS3*.[73](#jbm410024-bib-0073){ref-type="ref"} Similar to bisphosphonate use in pediatric cases of OI discussed previously, this case report of a bisphosphonate‐associated AFF in an adolescent raises the concern of long‐term safety of these agents in children.

Candidate gene studies {#jbm410024-sec-0015}
----------------------

Three studies have been conducted to search for variants in selected genes in patients with AFFs. All 3 studies included *ALPL* mutation analysis, with 1 study also including *COL1A1, COL1A2*, and *SOX9* genes (Table [3](#jbm410024-tbl-0003){ref-type="table"}).

###### 

Genetic Studies in AFF Cohorts and Their Findings

  Author, year                                                          Cases of AFF, *n*   Genetic analysis                             Major findings
  --------------------------------------------------------------------- ------------------- -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Roca‐Ayats et al. 2017[28](#jbm410024-bib-0028){ref-type="ref"}       6 (3 sisters)       Whole exome sequencing                       37 rare mutations in 34 genes were identified, including: GGPS1, CYP1A1, MVD, FN1, SYDE2, NGEF (the remaining 28 genes were not published)
  Lau et al. 2017[29](#jbm410024-bib-0029){ref-type="ref"}              2 sisters           Whole exome sequencing                       Novel rare homozygous variant in CTSK gene (C.784 + 3A \> C) was identified
  Perez‐Nunez et al. 2015[80](#jbm410024-bib-0080){ref-type="ref"}      13                  Exon array analysis                          Rare variants were more common in AFF cases compared to a control group (*n *= 268), and several rare variants tended to accumulate in AFF cases Variants in 20 genes associated with AFF were identified: PPEF2, ACOXL, GGA3, LIPN, DOCK2, CCDC147, OR51T1, PCK2, CRYBB2, CXCR7, EDC3, SF3B3, SLC15A5, SLC2A6, FOXK2, CNGB1, NAT8B, HHAT, OR2L13, SYTL2
  Funck‐Brentano et al. 2016[78](#jbm410024-bib-0078){ref-type="ref"}   5                   ALPL, COL1A1, COL1A2, SOX9 gene sequencing   Heterozygous mutation in COL1A2 (c.213G \> A; p.Arg708GIn) in 1 case
  Bhattacharyya et al. 2016[77](#jbm410024-bib-0077){ref-type="ref"}    10                  ALPL gene sequencing                         No mutations found
  Sum et al. 2013[75](#jbm410024-bib-0075){ref-type="ref"}              11                  ALPL gene sequencing                         Heterozygous mutation in ALPL gene (c.648 + 1G \> A) in 1 case
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Because inorganic pyrophosphate is a structural analog of bisphosphonates and femoral fractures with atypical features occur in cases of hypophosphatasia without prior antiresorptive therapy, it has been hypothesized that this condition is a genetic risk factor for AFF. The exact prevalence of mutations in the *ALPL* gene in the general population is unknown, but in the European population, it is estimated that the prevalence of mild forms of hypophosphatasia is 1:6300.[74](#jbm410024-bib-0074){ref-type="ref"} Carriers of mutations in the *ALPL* gene with a mild phenotype may be asymptomatic.

At the annual meeting of the ASBMR in 2013, an abstract was presented by Sum and colleagues[75](#jbm410024-bib-0075){ref-type="ref"} on prospective *ALPL* analysis in 11 patients with bisphosphonate‐associated AFFs. All coding exons and adjacent splice sites were sequenced in these individuals. In 1 patient, a single mutation was found affecting the donor splice site in exon 6 that is reported in lethal infantile hypophosphatasia when associated with a second missense mutation on the other chromosome.[76](#jbm410024-bib-0076){ref-type="ref"} The patient was a 66‐year‐old woman with ALP levels between 33 and 40 U/L (range 35 to 129 U/L) while on bisphosphonate therapy. Bone mineral density was in the osteopenic range. Vitamin B6 status was not reported. The conclusion of this finding was that mutations of *ALPL* associated with subclinical hypophosphatasia may rarely result in bisphosphonate‐associated AFFs.

In 2016, Bhattacharyya and colleagues[77](#jbm410024-bib-0077){ref-type="ref"} published on a retrospective case‐control study that investigated hypophosphatasia as a risk factor for AFFs. Controls (*n* = 13) without an AFF had used bisphosphonates for at least 5 years. Patients (*n* = 10) had sustained a complete AFF while using bisphosphonates, and 3 patients were continuing bisphosphonate treatment. In both patients and controls, a standardized history, physical exam, and standing long leg radiographs were performed. Additionally, levels of ALP and pyridoxal 5\' phosphate were measured. Participants withheld vitamin supplementation for at least 1 week before the blood test because this can affect pyridoxal 5\' phosphate levels. DNA testing was performed in all patients with AFF (*n* = 10). Because of the high costs of genetic testing, analysis of *ALPL* was only performed in the controls who had low(‐normal) serum ALP levels \<60 U/L, which was found in 9 of 13. Serum ALP \<50 U/L was considered abnormal in this study.

Mean ALP levels in AFF patients and controls were 58 U/L (range 37 to 73) and 56 U/L (38 to 74), respectively. Five of 10 AFF cases (50%) had an ALP level \<50 U/L versus 5 of 13 controls (38%). Despite cessation of vitamin supplementation, pyridoxal 5\' phosphate level was elevated in 2 controls with low ALP who used multivitamins on a regular basis. No mutations of the *ALPL* gene were found in either the AFF patients or controls. Four different coding variants in the *ALPL* gene were found in patients and controls, which had an allele frequency of 0.1 or higher in a cohort with 4300 European American samples (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA, USA). Rare variants are usually defined by a minor allele frequency (MAF) \<0.01, whereas variants with a MAF \>0.05 are considered common and less common variants have a MAF of 0.01 to 0.05.

The 4 coding variants were found in equal frequencies in the AFF group versus the control group; rs1780316 (1.00 versus 0.94), rs3200254 (0.20 versus 0.17), rs3200255 (0.2 versus 0.17), and rs34605986 (0.10 versus 0.00). A post hoc analysis revealed that in this study a 40% prevalence of *ALPL* mutations in AFF patients would have been needed to detect a difference with 80% power.

These results suggest that the low ALP levels in this study population are most likely related to antiresorptive treatment rather than an underlying mild form of hypophosphatasia.

In this study, no evidence was found for hypophosphatasia as a risk factor for AFFs. However, considering the small sample size and ensuing lack of power in this study, *ALPL* cannot be ruled out as a potential susceptibility gene based on these results.

In a study by Funck‐Brentano and colleagues in 2016,[78](#jbm410024-bib-0078){ref-type="ref"} the *ALPL*, *COL1A1*, *COL1A2*, and *SOX9* genes were sequenced in 4 females and 1 male with AFF. Fourteen AFF cases were identified by reviewing radiographs of patients with femoral fractures in three academic hospitals in France between 2007 and 2010, but only 5 patients gave consent for genetic testing. The rationale for *ALPL* and *COL1A1/1A2* testing in AFFs has been discussed above. *SOX9* plays a role in chondrocyte differentiation and regulation of the anti‐Mullerian hormone (AMH). Mutations in this gene are associated with campomelic dysplasia, a syndrome characterized by skeletal malformations and sex reversal.

One patient carried a heterozygous missense mutation in *COL1A2* that was found in the NHLBI GO Exome Sequencing Project (ESP) with a MAF of 0.0008 (rs72658163; c.2123G\>A;p.Arg708Gln). Apart from short stature (146 cm), the 78‐year‐old patient had no specific physical features of OI. Vertebral fracture status in this patient is not reported. She also had a single nucleotide polymorphism (SNP) in the *ALPL* gene that does not alter the protein (rs370212283; MAF 0.0002 in ESP). She had used risedronate for at least 5 years. The potential pathogenicity of the missense variant in *COL1A2* is unclear. Initially it was regarded as a pathogenic variant in Marfan syndrome or OI. However, because this variant was also found in unaffected or mildly symptomatic family members, it was later considered not clinically relevant or possibly a genetic modifier, having small effects on the expression level of other, disease‐causing genes. In cultured dermal fibroblasts of two unrelated heterozygous carriers of this variant, the diameter of the collagen fibrils was approximately 20% of control collagen fibrils.[79](#jbm410024-bib-0079){ref-type="ref"} This may imply that this variant affects connective tissue structure and is possibly involved in collagen‐related disorders.

In another patient, six common variants of the *ALPL* gene were detected, including a nonprotein‐altering variant, present in the Exome Aggregation Consortium (ExAC) with a MAF of 0.17 or higher (rs3200254; rs2275377; rs2275376; rs74063111; rs75829132; rs3200255). Another patient had a different nonprotein‐altering variant in the *ALPL* gene (rs3200256; MAF 0.01 in ExAC). In 2 patients, no genetic variants were found. No variants were found in *COL1A1* and *SOX9*.

Although this was a small cohort study, genetic testing of 4 genes identified a previously reported mutation in *COL1A2* and common variants in the *ALPL* gene, supporting the hypothesis that AFF populations are enriched with variants in genes associated with monogenetic diseases.

Exon array analysis {#jbm410024-sec-0016}
-------------------

In a pilot study, Pérez‐Núñez and colleagues[80](#jbm410024-bib-0080){ref-type="ref"} conducted an exon array analysis (Affymetrix Axion 2.0 exome array) in 13 women with AFFs and 268 controls that consisted of healthy women (*n* = 87) and patients with postmenopausal osteoporosis without AFFs (*n* = 181) (Table [3](#jbm410024-tbl-0003){ref-type="table"}). By including the osteoporosis patients in the control group, the investigators intended to avoid the finding of osteoporosis‐related variants rather than variants associated with AFFs. The analysis was restricted to variants with a minor allele frequency \<0.03 in the overall study population. Twenty‐one SNPs in 20 genes were defined as risk variants based on the arbitrary threshold of a *p* value \< 0.0025. However, only one variant remained statistically significant after correction for multiple testing, a missense variant in the *PPEF2* gene, which has no known function in bone metabolism. The distribution of these less common variants in cases and controls was statistically significantly different. In 12 of 13 AFF cases, three or more risk variants were present. In 15.7% (*n* = 42) of the control group, one risk variant was present, but none of the controls had more than one risk variant. The genes involved are not linked to known bone disorders, although the authors suggested that a possibly damaging missense variant in the *HHAT* gene, belonging to the hedgehog protein family, may be connected to developmental bone defects, while another possibly damaging missense variant in the *CXCR7* gene (also known as *ACKR3*) modulates the activity of precursor osteoblasts. These findings indicate that several variants combined may be associated with (a higher risk of) AFF. Based on these results, the authors concluded that AFFs have a polygenic background. However, this study is also limited by a small sample size and lack of functional studies to understand the potential mechanisms leading to AFF.

Whole‐exome sequencing {#jbm410024-sec-0017}
----------------------

To date, only one study has been published on whole‐exome sequencing in patients with bisphosphonate‐associated AFFs[28](#jbm410024-bib-0028){ref-type="ref"} (Table [3](#jbm410024-tbl-0003){ref-type="table"}). Exome sequencing may lead to the discovery of yet unknown genetic variants related to the risk of AFFs, although potential susceptibility variants for AFFs in noncoding regions and regulatory areas of the genome may still be missed.

In a recent letter to the editor by Roca‐Ayats and colleagues,[28](#jbm410024-bib-0028){ref-type="ref"} results were presented of a whole‐exome sequencing study in 3 sisters with bisphosphonate‐associated AFFs and in 3 unrelated patients with AFF after long‐term bisphosphonate treatment. Rare, protein‐altering mutations shared only by the 3 sisters were considered in this analysis. A dominant model was assumed by the authors. In total, 37 rare mutations were detected in 34 genes including a novel missense variant (p.Asp188Tyr) in geranylgeranyl diphosphate synthase 1 (*GGPS1*), a gene encoding for the enzyme geranylgeranyl pyrophosphate synthase (GGPPS). GGPPS catalyzes the formation of geranylgeranyl pyrophosphate in the mevalonate pathway. This novel variant is expected to severely impair GGPPS enzyme activity, potentially impairing osteoclast function (Fig. [2](#jbm410024-fig-0002){ref-type="fig"}). However, when the mutation in *GGPS1* is believed to decrease osteoclast function, it might also be expected that the siblings have a high bone mineral density and an osteopetrosis‐like phenotype, which is not evident from the case description in this letter.

In addition, the authors describe a mutation of the gene encoding *CYP1A1* in the 3 sisters and in 1 unrelated patient with AFF. Also, in 1 unrelated patient with an AFF, they identified a mutation encoding mevalonate diphosphate decarboxylase (*MVD*). Pathway analysis of the mutated genes showed enrichment of the isoprenoid biosynthesis, which proceeds through the mevalonate pathway in humans, including *GGPS1*, *CYP1A1*, and *MVD*.

According to Roca‐Ayats and colleagues, missense changes in the *FN1, SYDE2*, and *NGEF* genes might also be relevant variants. However, the authors do not discuss the potential mechanism of action of these variants with regard to the pathophysiology of AFFs. An overview of all found rare variants is not presented in this letter. Replication of the novel *GGPS1* mutation and the other 36 genetic variants in other cases of AFFs could provide evidence that 1 or more of these variants are potential susceptibility genes for AFFs. Otherwise, several variants may only be a result of shared DNA amongst the 3 siblings.

It is also possible that the *GGPS1* is a private mutation in this family and related to the underlying bone disease, not necessarily to the AFFs. However, it is plausible that the mutation is related to AFFs because the mevalonate pathway is believed to be inhibited by bisphosphonates containing a nitrogen side‐chain, such as alendronate, risedronate, and zoledronate. The novel *GGPS1* variant would possibly disrupt a binding site for magnesium of the GGPPS enzyme so that binding of farnesyl pyrophosphate and catalysis are disturbed. Blocking the farnesyl diphosphate synthase in this pathway induces the apoptosis of osteoclasts, decreasing bone resorption. In theory, this mutation could lead to a further accumulation of the mevalonate pathway substrate, isopentenyl pyrophosphate. In the literature, this substrate may indirectly activate T lymphocytes and is considered the cause of bisphosphonate‐induced acute phase reaction in patients on intravenous treatment.[81](#jbm410024-bib-0081){ref-type="ref"}, [82](#jbm410024-bib-0082){ref-type="ref"} It has been suggested that this mechanism may result in chronic immune stimulation and compromised immunity in patients on long‐term bisphosphonate therapy, which may contribute to another bisphosphonate‐associated adverse event, such as osteonecrosis of the jaw.[81](#jbm410024-bib-0081){ref-type="ref"}, [82](#jbm410024-bib-0082){ref-type="ref"}

Whole‐exome sequencing in another family of AFFs was presented in an abstract at the Australian New Zealand Bone & Mineral Society Annual Meeting in 2017[29](#jbm410024-bib-0029){ref-type="ref"} (Table [3](#jbm410024-tbl-0003){ref-type="table"}). Lau and colleagues described a consanguineous family in whom three siblings sustained bilateral AFFs without a history of bisphosphonate exposure. Whole‐exome sequencing of two siblings revealed a novel homozygous variant in the splice site of exon 6 of the cathepsin K gene (*CTSK*) (c.784+3A\>C), with a variant frequency of 0.0000577. Mutations in *CTSK* are associated with pycnodysostosis, and although the authors reported that the proband had short stature and high bone mass (*T*‐scores of +2.02 at the femoral neck and +2.75 at the lumbar spine), the proband had no other dysmorphic, clinical, or radiographic features to suggest this condition. This finding supports our hypothesis that individuals who sustain AFFs may carry a rare variant associated with a monogenetic bone disorder.

Conclusion {#jbm410024-sec-0018}
==========

Although AFFs are rare fractures associated with antiresorptive therapy, fear of this complication has been linked to the poor uptake of this effective treatment for osteoporosis. The pathogenesis of AFFs has not yet been elucidated, and the future challenge lies in improving our understanding of the association with antiresorptive therapy and the predisposing risk factors, including genetic factors, in order to prevent these fractures from occurring.

Here we summarize the evidence for genetic factors in AFFs. These fractures can occur in patients with monogenetic bone diseases, even without prior bisphosphonate exposure and in some cases unmasking the underlying condition. Targeted sequencing of some of these genes in AFF populations have identified variants in *CTSK*, *COL1A2*, and *ALPL* genes, and we propose that mild, unrecognized forms of such monogenetic bone diseases may underlie the etiology of AFFs. Further, whole‐exome sequencing and exon array analysis of AFF cohorts have identified novel genes that may predispose to AFFs, including genes related to the mevalonate pathway. These findings provide new insights into the pathogenesis of AFF. It is important that these initial findings can be replicated in future studies, in order to determine the exact genetic architecture of this rare complication. Consequently, a simple genetic test can be developed with all potential susceptibility variants involved. This test could be used to screen patients before prescribing (long‐term) treatment with bisphosphonates or denosumab.

Identification of susceptibility genes predisposing to AFFs may provide a solution in detecting patients at greatest risk of AFFs by genetic testing, for whom alternative anabolic treatment should be recommended. To date, genetic studies in AFF cases have comprised small cohorts. An international, multicentered collaborative study of well‐phenotyped AFF cases and controls is needed to detect rare variants associated with AFFs, as well as common variants in multiple genes. This would enable future targeting of antiresorptive therapy to those with low AFF risk.
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